Trimethyl(propyl)azanium | 20064-29-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Trimethyl(propyl)azanium
• CAS: 20064-29-3
• 化学式: C6H16N+
• 分子量: 102.2
• InChiKey: GSBKRFGXEJLVMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] TGR5 AGONISTS<br/>[FR] AGONISTES DE TGR5
  申请人：EXELIXIS INC

  公开号：WO2011071565A1

  公开（公告）日：2011-06-16

  TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

  TGR5激动剂的结构式VIII(Q)，其中X、R1、R2和R5在规范中定义，其药用盐、组合物以及用于治疗疾病的化合物和组合物的使用。该发明还包括在制药品中使用这些化合物以及用于制造药物，特别是用于治疗疾病。
• [EN] DELIVERY OF TARGET SPECIFIC NUCLEASES<br/>[FR] ADMINISTRATION DE NUCLÉASES SPÉCIFIQUES À UNE CIBLE
  申请人：SANGAMO THERAPEUTICS INC

  公开号：WO2018107026A1

  公开（公告）日：2018-06-14

  Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.

  本发明描述了包含阳离子脂质和其他脂质的脂质纳米颗粒，以及包含工程核酸酶以促进核酸向细胞的转移。
• [EN] LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS<br/>[FR] LIPIDES DESTINÉS À ÊTRE UTILISÉS DANS DES FORMULATIONS NANOPARTICULAIRES LIPIDIQUES
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2019036028A1

  公开（公告）日：2019-02-21

  Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein G1, G1', G2, G2', G3, L1, L1', L2, L2', X, X', Y and Y' are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

  提供具有以下结构（I）或其药物可接受的盐、互变异构体或立体异构体的化合物，其中G1、G1'、G2、G2'、G3、L1、L1'、L2、L2'、X、X'、Y和Y'按本文中定义。还提供了这些化合物作为脂质纳米粒子制剂组成部分用于递送治疗剂的应用，包含这些化合物的组合物及其使用和制备方法。
• ANTIMICROBIAL CATIONIC POLYCARBONATES
  申请人：INTERNATIONAL BUSINESS MACHINES CORPORATION

  公开号：US20140301967A1

  公开（公告）日：2014-10-09

  Antimicrobial cationic polymers having one or two cationic polycarbonate chains were prepared by organocatalyzed ring opening polymerization. One antimicrobial cationic polymer has a polymer chain consisting essentially of cationic carbonate repeat units linked to one or two end groups. The end groups can comprise a covalently bound form of biologically active compound such as cholesterol. Other antimicrobial cationic polymers have a random copolycarbonate chain comprising a minor mole fraction of hydrophobic repeat units bearing a covalently bound form of a vitamin E and/or vitamin D2. The cationic polymers exhibit high activity and selectivity against Gram-negative and Gram-positive microbes and fungi.

  具有一个或两个阳离子聚碳酸酯链的抗菌阳离子聚合物是通过有机催化的环氧开聚合制备的。其中一种抗菌阳离子聚合物具有基本由阳离子碳酸酯重复单元构成的聚合物链，与一个或两个末端基团相连。末端基团可以包括胆固醇等生物活性化合物的共价结合形式。其他抗菌阳离子聚合物具有随机共聚碳酸酯链，其中含有少量疏水重复单元，带有维生素E和/或维生素D2的共价结合形式。这些阳离子聚合物对革兰氏阴性和革兰氏阳性微生物和真菌表现出高活性和选择性。
• METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS
  申请人：TUFTS MEDICAL CENTER

  公开号：US20160052982A1

  公开（公告）日：2016-02-25

  The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

  本申请提供了制备可溶性脂质化配体药剂的方法，包括配体实体和脂质实体，并在某些实施例中提供了这些组分的相关参数，从而使得能够适当选择组分来组装出针对任何感兴趣的靶点的活性药剂。